Circulating Heparan Sulphate as a Predictor of Acute Kidney Injury in Critically Ill Septic Patients

Authors

  • Popescu M Department of Nephrology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Author
  • Renaud L Department of Intensive Care Medicine, University of Lyon, Lyon, France Author
  • Ozols S Department of Clinical Biochemistry, University of Latvia, Riga, Latvia Author

DOI:

https://doi.org/10.5281/zenodo.22644260

Keywords:

heparan sulphate, endothelial glycocalyx, sepsis-associated acute kidney injury, syndecan-1, heparanase

Abstract

Background: Acute kidney injury (AKI) complicates a majority of intensive care unit admissions for sepsis and independently
worsens survival, yet creatinine- and urine output-based diagnostic criteria detect renal injury only after substantial nephron
damage has occurred. The endothelial glycocalyx, whose principal glycosaminoglycan constituent is heparan sulphate, is degraded
early in sepsis by heparanase and related sheddases, releasing fragments into blood and urine that may report on renal
microvascular injury before functional decline is evident. Objective: To synthesise the published literature on circulating and
urinary heparan sulphate, and its surrogate shed syndecan-1, as predictors of AKI in critically ill septic patients. Methods: A
narrative review of mechanistic, epidemiological, and clinical cohort studies addressing heparan sulphate biology,
heparanase-mediated renal glycocalyx shedding, and the diagnostic and prognostic performance of heparan sulphate-related
biomarkers for sepsis-associated AKI (SA-AKI). Findings: SA-AKI affects over 60% of septic intensive care admissions in
contemporary multicentre cohorts and carries mortality risk that scales with injury severity. Heparanase-mediated cleavage of
renal endothelial heparan sulphate is detectable early in the septic course and precedes measurable changes in glomerular
filtration. Cohort studies report that circulating syndecan-1 and heparin-binding protein independently predict incident AKI and
need for kidney support therapy, with areas under the receiver operating characteristic curve (AUC) of 0.66-0.72 for single markers,
rising to 0.77-0.91 when combined with renal resistive index, angiopoietin-2, or organ-dysfunction scores. A large trial-embedded
analysis of the CLOVERS trial demonstrated a graded, dose-dependent association between baseline plasma heparan sulphate and
90-day mortality (9.9% to 44.2% across tertiles) that was independent of randomised fluid resuscitation strategy. Conclusions:
Circulating and urinary heparan sulphate constitute biologically plausible and empirically supported predictors of AKI in septic
critical illness, with best performance achieved in multimarker combinations. Assay standardisation and interventional trials
testing biomarker-guided management are needed before routine clinical adoption.

References

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 315(8):801-810, DOI:10.1001/jama.2016.0287.

Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements, 2(1):1-138, DOI:10.1038/kisup.2012.1.

Reitsma S, Slaaf DW, Vink H, van Zandvoort MAMJ, oude Egbrink MGA (2007) The endothelial glycocalyx: composition, functions, and visualization. Pflügers Archiv - European Journal of Physiology, 454(3):345-359, DOI:10.1007/s00424-007-0212-8.

Song JW, Zullo JA, Lipphardt M, Dragovich M, Zhang FX, Fu B, Goligorsky MS (2018) Endothelial glycocalyx-the battleground for complications of sepsis and kidney injury. Nephrology Dialysis Transplantation, 33(2):203-211, DOI:10.1093/ndt/gfx076.

Yilmaz O, Afsar B, Ortiz A, Kanbay M (2019) The role of endothelial glycocalyx in health and disease. Clinical Kidney Journal, 12(5):611-619, DOI:10.1093/ckj/sfz042.

Lygizos MI, Yang Y, Altmann CJ, Okamura K, Hernando AA, Perez MJ, Smith LP, Koyanagi DE, Gandjeva A, Bhargava R, Tuder RM, Faubel S, Schmidt EP (2013) Heparanase mediates renal dysfunction during early sepsis in mice. Physiological Reports, 1(6):e00153, DOI:10.1002/phy2.153.

Wang Y, Zhang Z, Qu X, Zhou G (2025) Role of the endothelial cell glycocalyx in sepsis-induced acute kidney injury. Frontiers in Medicine, 12:1535673, DOI:10.3389/fmed.2025.1535673.

Song MJ, Jang Y, Legrand M, Park S, Ko R, Suh GY, Oh DK, Lee SY, Park MH, Lim CM, Jung SY, Lim SY (2024) Epidemiology of sepsis-associated acute kidney injury in critically ill patients: a multicenter, prospective, observational cohort study in South Korea. Critical Care, 28(1):383, DOI:10.1186/s13054-024-05167-9.

Schmidt EP, Overdier KH, Sun X, Lin L, Liu X, Yang Y, Ammons LA, Hiller TD, Suflita MA, Yu Y, Chen Y, Zhang F, Burlew CC, Edelstein CL, Douglas IS, Linhardt RJ (2016) Urinary Glycosaminoglycans Predict Outcomes in Septic Shock and Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine, 194(4):439-449, DOI:10.1164/rccm.201511-2281OC.

Li JC, Wang LJ, Feng F, Chen TT, Shi WG, Liu LP (2023) Role of heparanase in sepsis-related acute kidney injury (Review). Experimental and Therapeutic Medicine, 26(2):1-11, DOI:10.3892/etm.2023.12078.

Sallee CJ, Noa AS, Bhowmik M, Nobles AC, Wang Z, Liu J, Richter JR, Blalock JE, Patel RP, Gaggar A, Richter RP (2026) Age-related differences in circulating heparanase-1 activity in sepsis and correlation with systemic vascular endotheliopathy. Frontiers in Medicine, 13:1893157, DOI:10.3389/fmed.2026.1893157.

Pajenda S, Figurek A, Wagner L, Gerges D, Schmidt A, Herkner H, Winnicki W (2020) Heparin-binding protein as a novel biomarker for sepsis-related acute kidney injury. PeerJ, 8:e10122, DOI:10.7717/peerj.10122.

Canbaz M, Orhun G, Polat Ö, Anaklı İ, Aydın AF, Kılınç S, Ergin Özcan P, Esen F (2025) The Prognostic Utility of Pathophysiologically Distinct Biomarkers for Renal Outcomes in Sepsis: A Prospective ICU Cohort Study. Journal of Clinical Medicine, 14(15):5370, DOI:10.3390/jcm14155370.

Semedi BP, Utariani A, Budi NS, Asmaningsih N, Andriyanto L (2021) Validity of Urine Syndecan-1 as A Predictor of Acute Kidney Injury In Pediatric Sepsis Patients. Indonesian Journal of Anesthesiology and Reanimation, 3(2):62-70, DOI:not assigned.

Hatanaka K, Ito T, Madokoro Y, Kamikokuryo C, Niiyama S, Yamada S, Maruyama I, Kakihana Y (2021) Circulating Syndecan-1 as a Predictor of Persistent Thrombocytopenia and Lethal Outcome: A Population Study of Patients With Suspected Sepsis Requiring Intensive Care. Frontiers in Cardiovascular Medicine, 8:730553, DOI:10.3389/fcvm.2021.730553.

Zhang R, Zhang Y, Tan J, Zhang D, Huang L, et al. (2025) Combined Plasma Syndecan-1 and Renal Resistive Index as Early Predictors of Sepsis-Associated Acute Kidney Injury: a prospective observational study. Research Square (preprint), DOI:10.21203/rs.3.rs-7083437/v1.

Salmito FTS, Mota SMB, Holanda FMT, Santos LL, Andrade LS, Meneses GC, Lopes NC, Araújo LM, Martins AMC, Libório AB (2024) Endothelium-related biomarkers enhanced prediction of kidney support therapy in critically ill patients with non-oliguric acute kidney injury. Scientific Reports, 14(1):4280, DOI:10.1038/s41598-024-54926-9.

Oshima K, Di Gravio C, Yan B, McMurtry SA, Burke R, et al. (2025) Endothelial Glycocalyx Degradation in Sepsis: Analysis of the Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) Trial, a Multicenter, Phase 3, Randomized Trial. Annals of the American Thoracic Society, 22(9):1382-1393, DOI:10.1513/AnnalsATS.202501-012OC.

Fernández-Sarmiento J (2025) Endothelial Glycocalyx Integrity as a Prognostic Key in Sepsis: New Insights from the CLOVERS Trial. Annals of the American Thoracic Society, 22(9):1303-1304, DOI:10.1513/AnnalsATS.202506-692ED.

Oshima K, Yan B, Tao R, Amorim G, Di Gravio C, McMurtry SA, Burke RC, Nam Y, Nikolli I, Kravitz MS, Stephenson D, Issaian A, Hansen KC, D'Alessandro A, Douglas IS, Self WH, Lindsell CJ, Leroux C, Ringor A, Matthay MA, Schildcrout JS, Shapiro NI, Schmidt EP (2026) Plasma chondroitin sulfate predicts the effectiveness of fluid resuscitation strategies in patients with sepsis. Journal of Clinical Investigation, 136(7):e202480, DOI:10.1172/JCI202480.

Downloads

Published

2025-06-15